Sanofi Diabetes Drug Improves Blood Sugar
Posted on: Tuesday, 5 December 2006, 15:02 CST
Sanofi-Aventis has revealed that patients with type 2 diabetes experienced significant improvements in blood sugar control and weight as well as other risk factors when administered its obesity drug Acomplia.
In the study, type 2 diabetes patients not currently treated with anti-diabetic medications and receiving Acomplia significantly lowered their HbA1c blood sugar levels by 0.8% from a baseline value of 7.9 as compared to a reduction of 0.3% in the placebo group. Over 50% of patients in the Acomplia arm of the trial achieved HbA1c levels below 7%, the target for good glucose control as recommended by the American Diabetes Association.
Importantly, these improvements in blood glucose control were accompanied by significant reductions in body weight of 6.7 kg in patients treated with Acomplia, while those patients on placebo lost only 2.7 kg. Furthermore, those on Acomplia benefited from improved good cholesterol and cut bad fat levels in the blood.
"The management of type 2 diabetes should not only focus on controlling blood sugar levels but also improve other risk factors such as weight, good and bad cholesterol, triglycerides and blood pressure," said Julio Rosenstock, Director of the Dallas Diabetes and Endocrine Center at Medical City.
Source: Datamonitor
Related Articles
- VIVUS' Qnexa Shows Significantly Improved Blood Sugar Control Through Weight Loss In Patients With Type 2 Diabetes
- ONGLYZA(TM) (Saxagliptin) Demonstrated Significant Improvements Across Key Measures of Glucose Control When Added to a Sulfonylurea or Thiazolidinedione in People With Inadequately Controlled Type 2 Diabetes
- One-Year Data Showed Investigational Use of Initial Combination Therapy With JANUVIA(TM) (Sitagliptin) and Metformin Significantly Improved Blood Sugar Control in Patients With Type 2 Diabetes Compared to Metformin Alone
- New Data Shows Rimonabant Benefited Patients With Type 2 Diabetes By Improving Blood Sugar Control, Reducing Weight and Acting on Other Cardiometabolic Risk Factors
- National Survey Finds Weight Gain, Patient-Provider Communication and New Medical Options Critical Factors for Controlling Type 2 Diabetes
- Diabetics' Blood Sugar Control and Cholesterol Levels Dramatically Improved By NAMCP Diabetes Patient Report Card(R) and a Web-Based Education Program
- Hormone linked to sugar control in diabetics
- Oral Meds Good for Controlling Type II Diabetes in Children
- Study on Pharmanex Tegreen 97(R) Finds Benefits in Blood Sugar Control and Weight Loss
- The CARDS Investigators: Primary Prevention of Cardiovascular Disease With Atorvastatin in Type 2 Diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre Randomised Placebo- Controlled Trial
 |
 |
User Comments (0)
RSS Feeds